TELO | Telomir Pharmaceuticals, Inc. Common Stock Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.52 - 4.82
52 Week Range	3.11 - 20.72
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	62,345
Average Volume	165,235
Shares Outstanding	29,752,670
Market Cap	136,267,229
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-04-09

Valuation
Profitability
Growth
Health
P/E Ratio	-5.95
Forward P/E Ratio	N/A
EPS	-0.77
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1
Country	USA
Website	TELO

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

*Chart delayed

Analyzing fundamentals for TELO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see TELO Fundamentals page.

Watching at TELO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TELO Technicals page.